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Lucio G. Costa is currently Professor of Environmental and Occupational Health Sciences at the School of Public
Health at the University of Washington. Dr. Costa is a renowned neurotoxicologist whose research interests are
focused on understanding the role of neurotoxic substances in neurodevelopmental disorders and other
neurological, neuropsychiatric and neurodegenerative diseases. Dr Costa’s research laboratory makes use of a
variety of in vivo and in vitro cell culture systems, transgenic animal models and imaging techniques to study the
cellular, biochemical and molecular mechanisms of neurotoxicity.
Michael Aschner is the Gray E. B. Stahlman Professor of Pediatrics and Pharmacology at Vanderbilt University School
of Medicine as well as a Senior Investigator at the Kennedy Center for Research on Human Development.
Dr Aschner’s research group has a particular interest in the neurobiology and physiology of astrocytes and the
signaling mechanisms associated with central nervous system injury. Dr Aschner’s laboratory studies metal uptake
and distribution in the brain, investigating the mechanisms of transport of methylmercury and manganese across
the capillaries of the blood–brain barrier. His research utilizes various experimental models (C. elegans, tissue
cultures and rodents) to understand the acute toxicity of manganese deposition in the brains of human neonates.
In this interview we find out a little more about the key issues in the field of toxicology research.How did you first become interested in
pharmacology and toxicology?
Lucio: I first became interested in pharmacology, a dis-
cipline which I thought was at the crossroad of medi-
cine, chemistry and biology. After my doctorate in
pharmacology, I was asked to consider a postdoctoral
position in a new laboratory at the University of Milano,
which was attempting to “launch” research in toxicology.
I found the field fascinating and well trenched into
everyday life. Indeed my first project was related to a
color used in a very common alcoholic drink.
Michael: As a graduate student in Neurobiology and
Anatomy I rotated in the laboratory of the late Dr. Patri-
cia Rodier. She was studying at the time the effects of
methylmercury on neurodevelopment, addressing the
antimitotic effects of this metal. I knew immediately this
was an area of interest to me and have stuck with it since,
through my postdoctoral years with “Mr. mercury”,
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distribution, and reproduction in any mediumWhy is it an exciting time to be involved in
toxicology in particular?
More than other areas of research, toxicology is interdis-
ciplinary. While solid foundations in chemistry and
biochemistry, biology, genetics, pathology and pharma-
cology are essential, they need to be integrated by
knowledge and expertise in diverse areas such as ex-
posure assessment, epidemiology, and public health. In
addition, there is a need to comprehend and integrate
the new “omics” disciplines into toxicological issues.
The ultimate goal is that of protecting the public from
the adverse effects of chemicals, by applying sound
scientific methods, and avoiding irrational and unjusti-
fied fears.
What challenges and developments can we
expect to see in the next few years in this field?
The main challenge probably remains that of determin-
ing to which extent and how exposure to chemicals may
contribute to disease. Two areas are particularly challen-
ging, related to early development and to aging. Expos-
ure in utero or in early childhood to chemicals is
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rate, and to other disease of adulthood, particularly dia-
betes and obesity. With the longer life expectancy, we
have also witnessed a substantial increase in neurode-
generative diseases. Whether some of these may be due
to environmental exposures throughout life, and to
gene-environment interactions, is an area of great im-
portance. Additional challenges for toxicology are, for
example, the need to develop new ways of testing for
toxicity of chemicals which should be faster, predictive,
and possibly inexpensive, and to respond to the increas-
ing use of new materials, particularly the nanomaterials,
which are finding an increasing number of applications.
How can novel toxicology research contribute to
meeting these challenges?
Toxicologists have come to realize that traditional tox-
icity testing, while it has served well the community over
the years, is too cumbersome for the thousands of chem-
ical entities on the market. Additionally, traditional tox-
icity testing is time-consuming, costly, and utilizes a
large number of animals. One of the novel areas of re-
search in toxicology is that of finding perturbation in
certain cellular pathways which may serve of “finger-
prints” of an ensuing disease. This task, which is rather
easy to envision, is proving to be extremely challenging
in its realization. Another area of research, which is not
new but that have not lost its importance, is that of bio-
markers, i.e. of early indicators of disease. Such measure-
ments, as all other aspects of toxicology, would much
benefit for increasing mechanistic research. As indicated,
animal use is under scrutiny for a number of reasons,
hence the challenge to developing and particularly, to
validating new alternative methodologies which utilize
in vitro systems or alternative animal species such as
worms (C. elegans).
How does toxicology contribute to the
development and safety assessment of new
therapeutic interventions?
Numerous companies are working to develop novel and
innovative drugs for treating diabetes, hypertension,
obesity, heart failure, hyperlipidemia, neurodegenerative
diseases and transplant rejection, to name a few. Current
approaches to toxicity testing and decision-making aim
to identify and/or support development of the best lead
candidates for human use. The identification of lead can-
didate and their therapeutic efficacy is largely based on
animal studies, where toxicology plays a key role. The
current approach to toxicity testing relies predominantly
on studies that aim to evaluate observable outcomes in
whole animals, such as clinical signs or pathologic
changes that are indicative of a disease state. In general,
failure in toxicology studies also represents the primaryreasons for the attrition of the most promising thera-
peutic agents from the drug development pipeline. It is
the lack of or the observation of treatment-related tox-
icity as evidenced most often in animal toxicology studies
that determines whether a candidate drug will move
along the pipeline to the next step, human trials.
What does the future hold for toxicology research
and what do you think are its limitations?
Toxicity testing of both potential therapeutics as well as
environmental contaminants is presently at a crossroads.
With the advents in biology and biotechnology, toxico-
genomics, epigenetics, and computational toxicology,
toxicity testing is poised to move from the traditional
animal testing (in vivo) to in vitro systems. Ideally, the
testing will likely take advantage of cell lines of human
origin. While by inference this approach will curtail the
usage of animals in toxicity testing, it has yet to be
determined how the new in vitro testing will meet chal-
lenges in evaluating various life stages, numerous health
outcomes, and large numbers of untested chemicals.
The new assays may be suited to assess measure simple
processes, such as binding of drugs or environmental
agents with cellular proteins and changes in gene ex-
pression caused by that binding, or they may measure
more integrated responses, such as cell division and cell
differentiation. Nevertheless, in order to be validated it
would have to be determined that they replicate in vivo
toxicity, a difficult task, as the in vitro systems represent a
highly reductionist approach. Notwithstanding this obs-
tacle, toxicity tests are expected to use high-throughput
methods, assessing cytotoxicity, cell proliferation and
apoptosis. Over time, as these systems become refined,
the need for traditional animal testing should be greatly
reduced.
Are there any particular papers you would like to
see submitted to your section?
We are interested in original research and review papers
that address the interactions of chemicals with biological
systems. The manuscripts may include basic research of
molecular mechanisms underlying normal and abnormal
physiology to define novel therapeutic targets; transla-
tional research to adapt observations from the laboratory
to patients; clinical research to examine the behavior of
novel therapeutics in humans; basic research to identify
molecular mechanisms and targets of xenobiotics; and
population research to identify health outcomes asso-
ciated with exposures to environmental agents and
xenobiotics. Articles on promising new approaches in al-
ternative toxicity testing are also welcome.
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